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Abstract  
Background  
Trial registration was introduced to reduce research bias by promoting trial transparency 
and accountability. We aimed to evaluate the frequency of, and factors associated with, trial 
registration and declaration of trial registration.  
Methods  
We selected all randomised controlled trials in kidney transplantation, published between 
October 2005 and December 2010 and determined if a trial was registered and if a trial 
declared their registration in subsequent trial reports.  
Results  
Of 307 eligible trials identified, 24% (74/307) were registered and of those 59% (44/74) 
contained trial registration details within at least one trial report. Trial registration was more 
likely for trials published more than once, in later years or reported in journals that followed 
the International Committee of Medical Journal Editors (ICMJE) guidelines. Trial registration 
was less likely for trials that did not declare their funding sources. Registered trials were 
more likely to declare registration details in related reports if published in later years, or in a 
journal that followed ICMJE guidelines. Trials that did not declare their funding sources were 
less likely to declare registration details.  
Conclusions  
Although still suboptimal, the situation is improving over time, with both trial registration 
and declaration of registration details more likely in later years.
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Introduction 
Trial registration is designed to reduce research bias by promoting research transparency 
and accountability (1, 2). The importance of trial registration has been highlighted since 
1986 (3), and in 2000 the US National Library of Medicine established the Web-based 
registry ClinicalTrials.gov to facilitate the registration of clinical trials (4). When the results of 
clinical trials are altered, suppressed or not published there is the potential for scientific 
misconduct, wasted resources and harmful outcomes for patients (5, 6). After decades of 
debate (7), in September 2004 the International Committee of Medical Journal Editors 
(ICMJE) announced that prospective trial registration would be a mandatory requirement 
for publication in a member journal for any trial beginning recruitment after July 2005 (8). 
For unregistered trials that began before July 2005, retrospective registration was allowed 
until September 2005 (8). Since then, the importance of trial registration has been further 
promoted by the World Health Organisation (WHO) (9), the Declaration of Helsinki (10), 
guidelines groups (11) and other editorial groups for example the World Association of 
Medical Editors (12) and Surgery Journal Editors Group (13).  
 
The WHO has defined a minimum amount of information that must appear in a register in 
order for a given trial to be considered fully registered (14). This includes information on the 
study intervention, inclusion and exclusion criteria as well as the predefined primary and 
secondary outcomes. This information allows users to compare important methodological 
features defined a-priori with those subsequently presented when trial results are 
published. While previous studies have evaluated the frequency of trial registration (15-17), 
none have evaluated the frequency with which trials declare their registration details in 
associated reports. Unless a trial’s registration details are available to users of research and 
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appear on all reports and documents associated with a trial, transparency of research 
practice is not maintained and it becomes very difficult to trace the life-cycle of a trial from 
design through to conduct and publication to ensure consistency.  Therefore, while trial 
registration is a vital first step in promoting transparency and accountability, for it to be 
effectively translated into practice, declaration of trial registration is equally important.   
For our study, we chose to study trial registration and the declaration of registration details 
in a medical specialty field, to reflect the perspective of users of clinical research, who use 
trial evidence to inform their decision-making in clinical practice. We chose the field of 
kidney transplantation, because it is a rapidly developing and technologically innovative 
field, and because trial results are typically published in both general medical and speciality 
journals. If the global efforts to encourage trial registration have been effective, we 
hypothesised that trials reported more recently were more likely to be registered and to 
declare their registration details in subsequent reports, compared with older trials.
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Results 
Characteristics of included trials 
Figure 1 illustrates the process of identification of trials and trial reports for this study. We 
identified 523 reports of 307 trials. The number of published reports per trial varied from 
one to 33. Ninety-eight percent (515/523) of trial reports identified were published articles 
available from 53 journals, the remainder were conference abstracts related to published 
trials. Table 1 displays the characteristics of the included trials and their related reports. 
 
Twenty-four percent of trials (74/307) were registered in a trial registry, and these trials 
were reported in 212 reports. Fifty-nine percent (44/74) of registered trials declared their 
trial registration details within at least one trial report. Seventy-four percent of (156/212) 
the reports for registered trials did not contain any indication of the relevant trial 
registration details. Table A in the supplementary material file details the performance of 
specific journals in relation to the publication of registered and unregistered trials and the 
declaration of trial registration identifiers. 
 
Factors associated with trial registration 
Table 2 displays the unadjusted OR and CI for factors associated with trial registration, while 
Figure 2 displays the adjusted OR and CI. Trials published more than once were more likely 
to be registered (2 reports- OR 3.1, CI 1.1 to 8.4. >2 reports- OR 14.6, CI 4.8 to 44.9; 
P<0.001), as were those that were reported in journals that followed ICMJE guidelines (OR 
7.4, CI 3.2 to 17.3; P<0.001) and published in later years (2007- OR 2.8, CI 1.0 to 7.7. 2008- 
OR 7.0, CI 2.2 to 21.7. 2009- OR 10.1, CI 2.4 to 43.1. 2010- OR 37.4, CI 8.0 to 175.6; P<0.001). 
Trial registration differed according the region in which the trial was conducted, P=0.01. 
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Trials conducted in the USA were significantly more likely to be registered than European 
trials (OR 6.4, CI 1.9 to 21.8). Trials conducted in other regions and globally were also more 
likely to be registered but not significantly so (Other regions – OR 1.8, CI 0.6 to 5.7. Global – 
OR 3.7, CI 0.9 to 14.6). Trial registration differed according to funding source, P<0.006. Trials 
which did not declare their funding source, were significantly less likely to have been 
registered (OR 0.2, CI 0.1 to 0.5), as were those that were commercially funded but not 
significantly so (OR 0.4, CI 0.1 to 1.1.). No interaction term proved significant on analysis. 
The model adequately fitted the data (Hosmer–Lemeshow goodness of fit test P=0.53). 
 
Factors associated with declaration of trial registration 
Table 2 displays the unadjusted OR and CI for factors associated with declaration of trial 
registration details within reports of registered trials, while Figure 3 displays the adjusted 
OR and CI. Trials that were registered were more likely to declare registration details in 
related reports if published in later years (2007- OR 6.3, CI 1.3 to 29.8. 2008- OR 4.6, CI 1.3 
to 16.0. 2009- OR 9.5, CI 1.8 to 50.1. 2010- OR 30.5, CI 5.9 to 158.7; P=0.002), or if published 
in a journal that followed ICMJE guidelines (OR 3.9, CI 1.6 to 9.6; P=0.003). Compared to 
European trials, trials conducted globally were significantly less likely to declare their 
registration details (OR – 0.3, CI 0.08 to 0.9). Trials conducted in the USA or other regions 
were no more or less likely to declare their registration details than European trials (USA- 
OR 0.7, CI 0.2 to 2.4. Other- OR 1.0, CI 0.3 to 3.3) Declaration of trial registration differed 
according to funding source, P=0.007. Trials which did not declare their funding source, 
were significantly less likely to declare their registration details (OR 0.1, CI 0.02 to 0.4), as 
were those that were commercially funded but not significantly so (OR 0.4, CI 0.2 to 1.1). No 
interaction term proved significant on analysis. The model adequately fitted the data 
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(Hosmer–Lemeshow goodness of fit test P=0.78). Exclusion of abstracts on sensitivity 
analyses did not results in qualitatively altered outcomes (data not shown). 
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Discussion 
Despite mandatory trial registration being endorsed in 2005 by the ICMJE (8), the majority 
(76%) of randomised controlled trials in kidney transplantation reported from 2005 to 2010 
were not prospectively registered, and even when registered frequently did not cite 
registration details in related reports (74%). After controlling for other factors, we found 
that trials where the funding source was not stated were less likely to be registered and 
when registered were less likely to declare their registration details in trial reports. Although 
still suboptimal, the situation is improving over time, with both trial registration and 
declaration of registration details more likely in later years. 
 
Consistent with our findings, previous research has shown low rates of trial registration (15-
17). Commercial funding is known to affect rates of publication and the size and direction of 
results presented (18-20). However, to our knowledge, no previous study has demonstrated 
a negative correlation between funding source and the uptake of trial registration or its 
subsequent declaration. This underutilisation of trial registration subverts the intention of 
bias minimisation and transparency in contemporary research. Additionally, the non-
declaration of a trial’s registration details when trial findings are published makes any 
potential manipulations less detectable to the reader.   
 
Our study has several limitations. First, as our analyses were based on data from reports of 
published trials, we have not included unpublished trials. Unpublished trials may differ from 
published trials in their rate of trial registration, although probably in the direction of less 
registration. Second, as our study is a retrospective cohort study, it is prone to more bias, 
for example, selection and measurement bias, than a prospective study (21). We attempted 
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to overcome these limitations using predefined hypotheses, inclusion criteria, study factors 
and analyses. Finally, our study only included trials related to kidney transplantation. 
Because of this, the generalisability of our results may be limited. However, we deliberately 
designed our study with this approach, in order to reflect the clinical reality of the end-users 
of research working in a medical specialty.  
 
If trial registration is going to increase transparency and scientific rigour, the evidence of 
trial registration needs to be available to users of research. This requires the co-operation of 
study investigators and journal editors. Our findings suggest that neither investigators nor 
editors implement best practice. To improve this situation, more journals need to make 
prospective trial registration a pre-requisite for publication and make trial registration 
details clearly visible in related reports. Currently, 910 journals unofficially ‘follow’ the 
ICMJE's uniform requirements for manuscripts submitted to biomedical journals 
(http://www.icmje.org/journals.html, accessed on the 01/01/2011). In the subset of trials 
included in our study, which were published in journals that followed ICMJE guidelines, only 
45% of trials were registered and of those 49% declared this in their publication, so clearly 
these journals are not fully implementing ICMJE policy. The success of trial registration will 
depend on all journals consistently implementing these policies. Therefore, we suggest that 
the ICMJE and other editorial groups encourage their affiliated journals to  enforce the 
implementation of their trial registration requirements.  
 
Although we disagree, some argue that because of the lack of repercussions and policing, 
the effect of trial registers is negligible and that study protocol changes, omissions and 
suppressions are the rule (22). Trial registers may even have a deterrent effect on 
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commercial incentives to conduct trials as the increased transparency means the conduct of 
a trial becomes public knowledge and the investment necessary for the conduct of a trial 
will be scrutinised by market forces to assess the opportunity cost of such an investment, 
resulting in fewer trials being conducted due to the increased risk (23). If open access to trial 
protocols via trial registries is an inadequate method to detect subsequent reporting bias 
(24), then trial registration by itself may be inadequate to prevent research misconduct. 
Multiple complementary methods are probably required to combat publication bias. One 
complementary alternative is to supply open-access to the raw data from a trial, so that 
anyone may scrutinize the presented results. Spurred on by the Wakefield debacle and 
other cases, where only prolonged investigation fully revealed gross data manipulation, the 
proposal to allow access to the raw data from trials has gained momentum (25, 26). Clearly, 
any efforts to improve reporting transparency in the medical community are desirable. The 
EQUATOR network (http://www.equator-network.org/about-equator/), seeks to promote 
transparent and accurate reporting of all research studies and is therefore an important 
central repository for such efforts, for example the Standardized Protocol Items for 
Randomized Trials (SPIRIT) initiative and the GPP2 guidelines, which promote unbiased and 
ethical reporting respectively (27, 28).  
 
The aim of trial registration is to increase trial transparency and accountability. Although the 
situation is improving over time, currently, the trial registration process is not being utilised 
wholly effectively, which means users of research are less able to identify protocol 
deviations. A concerted effort from all parties, to increase education, awareness, 
implementation and utilisation of trial registration and its principles is necessary to produce 
higher quality research. It remains to be seen whether other efforts such as the proposal to 
 14 
allow access to trial data or the use of reporting guidelines, will improve trial transparency 
and accountability. 
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Materials and Methods 
Study sample 
We conducted a cohort study of all randomised controlled trials in kidney transplantation, 
published at least once in a journal, between October 2005 and December 2010. We 
identified these trials from the Cochrane Renal Group’s specialised register. This register is 
updated daily and contains records of randomised trials in nephrology, identified from 
searches of MEDLINE, Embase and CENTRAL. In addition, records identified from hand 
searching of selected journals and the proceedings of major conferences are continuously 
added to the specialised register (29). We chose the lower limit of October 2005 for 
publication as according to ICMJE policy all trials (both those initiated before and after July 
2005) should have been registered by September 2005 (8). We chose the upper limit of 
December 2010 for publication to reduce any selection bias that might arise due to 
potential differences among medical specialty journals due to a time lag from publication to 
indexing by the National Library of Medicine (last search May 2011). Once all eligible trials 
were identified, we retrieved any additional reports, including journal articles and 
conference abstracts that related to that trial. We excluded trials that were published only 
as conference abstracts. To create a cohort of comparable studies, we excluded trials 
reported only in a language other than English, trials of other solid organ transplants, and 
trials where the unit randomised was not a transplant recipient. We established the 
registration status of each trial by conducting investigator and title searches of the WHO 
International Clinical Trials Registry Platform (ICTRP: http://apps.who.int/trialsearch/) 
between 25/11/09 and 14/05/2011. Trials not found through the WHO ICTRP were 
considered unregistered. Subsequently, for trials that were registered, we examined all 
published reports that related to that trial for the presence of trial registry identifiers, to 
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determine if trial registration details had been declared. Data collection and analysis was 
conducted by one author and checked by another, without blinding to the trial names or 
authors.  
 
Data analysis 
As many trials are reported more than once, we first identified reports from the same trial 
using trial characteristics (such as sample size, study intervention, location of trial, study 
population, etc.) and then grouped them. To determine the factors associated with trial 
registration we conducted logistic regression analyses, with the trial as the unit of analysis. 
We considered the following study factors: number of reports per trial (1, 2, >2), sample size 
(<200, ≥200), earliest date of publication (<2007, 2007, 2008, 2009, 2010), funding source 
(investigator, commercial, not stated), whether the primary outcome favoured the 
intervention (p value <0.05, or not), region in which the trial was conducted (global or >2 
continents, USA, Europe, other) and whether the trial had at least one report in a journal 
affiliated with the ICMJE (determined either by the journal being listed on ICMJE website on 
06/01/2010 or as stated or implied from each journal’s ‘instructions to authors’). In 
attributing trial funding source, where trials were funded by both investigator and 
commercial sources we recorded the trial as commercially funded. Trial funding source was 
recorded from trial reports, trial declarations and conflict of interest statements. The 
primary outcome of a trial was identified as the outcome reported as such from the trial 
report or if this was unclear from the sample size calculation. The earliest year of trial 
publication entered and remained in the adjusted analyses regardless of statistical 
significance, as calendar year was central to our research question. To allow for potential 
effect modification among study factors, we pre-specified potential interaction terms. We 
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hypothesised that commercially funded trials were more likely to be larger and reported 
more than once; hence we considered potential for commercial funding source being 
associated with multiple reports, and commercial funding source being associated with 
larger sample size. 
To determine the factors associated with declaration of trial registration details within trial 
reports we  conducted logistic regression analyses using generalised estimating equations. 
The unit of analysis  was the trial report and adjusted for any clustering effect that might be 
present due to multiplicity of reports within trials via a sandwich estimator (30). We 
considered the following study factors using the same categories and rules as with the first 
model: number of reports per trial, sample size, date of publication, funding source, 
whether the primary outcome reported favoured the intervention, region in which the trial 
was conducted and whether the trial report was published in a journal affiliated with the 
ICMJE. To allow for potential effect modification among study factors, we pre-specified 
potential interaction terms. In line with existing studies (16, 17, 29-31), we hypothesised 
that commercially funded trials were more likely to reach conclusions favouring the drug 
than non-commercially funded trials. Therefore, we considered potential for commercial 
funding source being associated with a statistically significant result.  
 
For both models, associations between the covariates and outcomes were reported as odds 
ratios (OR) with 95% confidence intervals (CI). All factors were considered in adjusted 
analyses if the unadjusted association showed P<0.25, and were sequentially eliminated 
using backward selection if adjusted association showed P>0.05. All P-values were 
calculated from Wald χ2 test statistics. The final models were checked using a Hosmer and 
Lemeshow goodness-of-fit test. To investigate the robustness of our analyses we repeated 
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our analyses excluding abstract reports. Statistical analyses were carried out using STATA 
software (Stata11, StataCorp LP, Texas, USA).
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Table 1: Characteristics of trials and related trial reports included in analyses 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a Unit of analysis is the trial. b Unit of analysis is the trial report.  
 Trials a (%) Reports of registered trials b (%) 
Total 307 trials 212 trial reports 
   
Registered   
    Yes 74 (24) 212 (100) 
    No 233 (76) - 
   
Journal   
   Transplantation  217 (71) 147 (69) 
   Nephrology  58 (19) 50 (24) 
   General medical 25 (8) 14 (7) 
   General surgical 7 (2) 1 (1) 
   
Publication status   
   Full text publication 307 (100) 204 (96) 
   Abstract/Conference proceeding - 8 (4) 
   
Intervention rationale   
   Immunosuppression 214 (70) 187 (88) 
   Hypertension 21 (7) 7 (3) 
   Infection 17 (6) 6 (3) 
   Endocrine 16 (5) 9 (4) 
   Other  39 (13) 3 (1) 
   
Year of publication   
   <2007 128 (42) 68 (32) 
   2007 67 (22) 43 (20) 
   2008 58 (19) 54 (25) 
   2009 29 (9) 19 (9) 
   2010 25 (8) 28 (13) 
   
Sample size   
   <200 235 (77) 67 (32) 
   ≥200 72 (23) 145 (68) 
   
Number of reports per trial  
   1 227 (74) 37 (17) 
   2   42 (14) 26 (12) 
   >2 38 (12) 149 (70) 
   
Published following ICMJE guidelines  
   No 170 (55) 128 (60) 
   Yes 137 (45) 84 (40) 
   
Region in which the trial was conducted   
   Europe 57 (19) 22 (10) 
   USA 56 (18) 62 (29) 
   Other 163 (53) 34 (16) 
   Global 31 (10) 94 (44) 
   
Funding source   
   Investigator 51 (17) 25 (12) 
   Commercial 122 (40) 171 (81) 
   Not stated 134 (44) 16 (8) 
   
Result in favour of primary outcome  
   Not significant 133 (43) 71 (33) 
   Significant 174 (57) 141 (67) 
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Table 2: Factors associated with trial registration and declaration of trial registration within reports of registered trials. 
 
a Unit of analysis is the trial. b Unit of analysis is the trial report. c P values based on the Wald chi-squared test statistic. 
d This is the group against which the other groups are compared. 
Trial characteristics 
Trial registration a Declaration of registration details in trial reports b 
(Total trials 307) (Total reports of registered trials 212) 
Not registered 
(%) 
Registered 
(%) 
Unadjusted odds 
ratio (95% CI) 
P value c 
Did not declare  
(%) 
Declared 
(%) 
Unadjusted odds 
ratio (95% CI) 
P value c 
Total  233 (76) 74 (24)   156 (74) 56 (26)  
Year of publication 
 <2007 103 (80) 25 (20) 1.0 (Referent)d <0.007 65 (96) 3 (4) 1.0 (Referent)d <0.001 
 2007 54 (81) 13 (19) 1.0 (0.5, 2.1)  32 (74) 11 (26) 7.4 (1.7, 32.3)  
 2008 44 (76) 14 (24) 1.3 (0.6, 2.8)  39 (72) 15 (28) 8.3 (2.3, 29.9)  
 2009 21 (72) 8 (28) 1.6 (0.6, 4.0)  11 (58) 8 (42) 15.8 (3.7, 66.8)  
 2010 11 (44) 14 (56) 5.3 (2.1, 12.9)  9 (32) 19 (68) 45.7 (9.5, 219.2)  
Sample size         
 <200 195 (83) 40 (17) 1.0 (Referent)d <0.001 40 (60) 27 (40) 1.0 (Referent)d 0.015 
 ≥200 38 (53) 34 (47) 4.4 (2.5, 7.7)  116 (88) 29 (12) 0.4 (0.2, 0.8)  
Number of reports per trial         
 1 190 (84) 37 (16) 1.0 (Referent)d <0.001 15 (41) 22 (59) 1.0 (Referent)d <0.001 
 2 29 (69) 13 (31) 2.3 (1.1, 4.8)  17 (65) 9 (35) 0.4 (0.1, 1.1)  
 >2 14 (37) 24 (63) 8.8 (4.2, 18.6)  124 (83) 25 (17) 0.1 (0.1, 0.3)  
Published following ICMJE guidelines       
 No 158 (93) 12 (7) 1.0 (Referent)d <0.001 113 (88) 15 (12) 1.0 (Referent)d <0.001 
 Yes 75 (55) 62 (45) 10.9 (5.5, 21.4)  43 (51) 41 (49) 7.2 (3.2, 16.3)  
Region in which the trial was conducted 
 Europe 41 (72) 16 (28) 1.0 (Referent)d <0.001 9 (41) 13 (59) 1.0 (Referent)d 0.01 
 USA 32 (57) 24 (43) 1.9 (0.9, 4.2)  45 (73) 17 (27) 0.3 (0.09, 0.8)  
 Other 143 (88) 20 (12) 0.4 (0.2, 0.8)  22 (65) 12 (35) 0.4 (0.1, 1.2)  
 Global 17 (55) 14 (45) 2.1 (0.8, 5.3)  80 (85) 14 (15) 0.1 (0.03, 0.4)  
Funding source 
 Investigator 35 (69) 16 (31) 1.0 (Referent)d <0.001 11 (44) 14 (56) 1.0 (Referent)d <0.003 
 Commercial 73 (60) 49 (40) 1.5 (0.7, 2.9)  131 (77) 40 (23) 0.2 (0.1, 0.6)  
 Not stated 125 (93) 9 (7) 0.2 (0.06, 0.4)  14 (87.5) 2 (12.5) 0.1 (0.02, 0.6)  
Result in favour of the primary outcome 
 Not significant 99 (74) 34 (26) 1.0 (Referent)d 0.6 41 (58) 30 (42) 1.0 (Referent)d <0.006 
 Significant 134 (77) 40 (23) 0.9 (0.5, 1.5)  115 (82) 26 (18) 0.3 (0.1, 0.7)  
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Figures legends 
Figure 1. Flow chart for identification of kidney transplantation randomised controlled trials published 
between October 2005 and December 2010. 
Figure 2. Factors associated with trial registration, adjusted analysis (odds ratios and 95% confidence 
intervals).  
Figure 3. Factors associated with declaration of trial registration in reports of registered trials, adjusted 
analysis (odds ratios and 95% confidence intervals). 
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Figures 
Figure 1. Flow chart for identification of kidney transplantation randomised controlled trials published 
between October 2005 and December 2010. 
 
 
 
 
 Randomised controlled trials of kidney 
transplantation, title and abstract screening 
 
908 
 
 
Randomised controlled trials of kidney transplantation 
reported between October 2005 and December 2010, 
full text examined 
 
658 
 
 
Excluded 
                                           
Reported prior to October 2005 203 
Reported after December 2010 47 
  
TOTAL 250 
 
 
 
Excluded                                        
 
Not a kidney transplantation 
randomised controlled trial 
14 345 
  
TOTAL 14 345 
 
Excluded                                                 
 
Additional organ transplant 7 
Donor study 32 
Organ study (e.g. perfusion fluid) 33 
Not a kidney transplantation 
randomised controlled trial 
25 
No full text available  11 
Only available on trial register 27 
  
TOTAL 135 
 
Included 
523 reports of 307 trials 
 
Registered trials     74 
Reports of registered trials    212 
Registered trials, which declared their trial 
registration details in at least one publication 44 
 
All records from Cochrane Renal Group’s study register 
December 2010 
 
15 253 
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Figure 2. Factors associated with trial registration, adjusted analysis (odds ratios and 95% confidence 
intervals).  
 
Note: * P values based on the Wald chi-squared test statistic.  
            Not registered      Registered  
                   n (%)                n (%)___     
P<0.001   103 (80) 25 (20) 
                  54 (81) 13 (19) 
     44 (76) 14 (24) 
     21 (72)   8 (28) 
     11 (44) 14 (56) 
P<0.001    190 (84) 37 (16) 
      29 (69) 13 (31) 
      14 (37) 24 (63) 
P<0.001     158 (93) 12 (7) 
       75 (55) 62 (45) 
P=0.01       41 (72) 16 (28) 
       32 (57) 24 (43) 
     143 (88) 20 (12) 
       17 (55) 14 (45) 
P<0.006       35 (69) 16 (31) 
       73 (60) 49 (40) 
     125 (93)   9 (7) 
Date of publication 
<2007 
2007 
2008 
2009 
2010 
Number of publications 
1 
2 
>2 
Followed ICMJE guidelines 
No 
Yes 
Trial location 
Europe 
USA 
Other 
Global 
Funding source 
Investigator 
Commercial 
Not stated 
0.01 0.1 0.5 1 2 10 100 
Trial registration* 
Odds ratios 
 28 
Figure 3. Factors associated with declaration of trial registration in reports of registered trials, adjusted 
analysis (odds ratios and 95% confidence intervals). 
 
Note: * P values based on the Wald chi-squared test statistic. 
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